GlassScriptPhysician profile
David A Gooray
NPI 1720070261
$332,652.51
in general payments reported to CMS, 2019-2025
34 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $51K · 2021: $42K · 2022: $31K · 2023: $23K · 2024: $15K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $4,725 · Travel and Lodging: $2,734 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,593.00 |
| Food and Beverage | $4,725.16 |
| Travel and Lodging | $2,734.45 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $123,526.77 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $115,024.70 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $68,592.95 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $10,056.35 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $4,677.01 | 2019-2022 | |
| Abbott Laboratories | $1,729.68 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,514.47 | 2019-2020 | |
| Atricure, INC. | $1,482.71 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $848.19 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $801.65 | 2019-2025 | Farxiga, Airsupra, Wainua |
| Merck Sharp & Dohme LLC | $774.88 | 2021-2025 | Verquvo, Belsomra |
| Novo Nordisk INC | $679.07 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $448.18 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Boston Scientific Corporation | $440.69 | 2019-2023 | |
| Gilead Sciences, INC. | $401.97 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $197.12 | 2023-2024 | Korlym |
| Scpharmaceuticals INC. | $169.94 | 2023-2025 | |
| Glaxosmithkline, LLC. | $153.02 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Lexicon Pharmaceuticals, INC. | $140.83 | 2023-2024 | Inpefa |
| Azurity Pharmaceuticals, INC. | $135.56 | 2023 | Edarbi, Horizant |
| Pfizer INC. | $135.15 | 2019-2025 | |
| Portola Pharmaceuticals, LLC | $126.13 | 2020 | |
| Bridgebio Pharma, INC. | $109.09 | 2025 | Attruby |
| Amarin Pharma, INC. | $94.46 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.53 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.53 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $51.13 | 2021-2022 | |
| Abbvie INC. | $49.68 | 2023-2024 | |
| Arbor Pharmaceuticals, INC. | $36.22 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $25.15 | 2019 | |
| Janssen Biotech, INC. | $24.15 | 2024 | Stelara |
| Mannkind Corporation | $22.23 | 2025 | |
| Heartflow, INC. | $20.44 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gooray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.